BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10838491)

  • 1. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H; Hohenberger P; Lochs H; Haboubi N; Berdel WE; Thiel E; Kreuser ED
    Oncology; 2000 May; 58(4):273-9. PubMed ID: 10838491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
    Blanke CD; Kasimis B; Schein P; Capizzi R; Kurman M
    J Clin Oncol; 1997 Mar; 15(3):915-20. PubMed ID: 9060528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.
    Hartung G; Hofheinz RD; Wein A; Riedel C; Rost A; Fritze D; Kreuser ED; Drees M; Kühnel J; Hehlmann R; Queisser W
    Onkologie; 2001 Oct; 24(5):457-62. PubMed ID: 11694772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD; Shultz J; Cox J; Modiano M; Isaacs R; Kasimis B; Schilsky R; Fleagle J; Moore M; Kemeny N; Carlin D; Hammershaimb L; Haller D
    Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
    Punt CJ; Keizer HJ; Douma J; Skovsgaard T; Schüller J; Muller EW; Ten Napel CH; Croles JJ; Lochs H; Zhang J; Hammershaimb L
    Ann Oncol; 2002 Jan; 13(1):81-6. PubMed ID: 11865814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
    Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
    J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
    Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
    Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.
    Jäger E; Klein O; Wächter B; Müller B; Braun U; Knuth A
    Oncology; 1995; 52(6):470-3. PubMed ID: 7478433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD; Messenger M; Taplin SC
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    Machiavelli MR; Salum G; Pérez JE; Ortiz EH; Romero AO; Bologna F; Vallejo CT; Lacava JA; Dominguez ME; Leone BA
    Am J Clin Oncol; 2004 Apr; 27(2):149-54. PubMed ID: 15057154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.